IL317018A - Gene therapy compositions and methods of use thereof - Google Patents
Gene therapy compositions and methods of use thereofInfo
- Publication number
- IL317018A IL317018A IL317018A IL31701824A IL317018A IL 317018 A IL317018 A IL 317018A IL 317018 A IL317018 A IL 317018A IL 31701824 A IL31701824 A IL 31701824A IL 317018 A IL317018 A IL 317018A
- Authority
- IL
- Israel
- Prior art keywords
- methods
- gene therapy
- therapy compositions
- compositions
- gene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
- C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
- C12N9/226—Class 2 CAS enzyme complex, e.g. single CAS protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263345003P | 2022-05-23 | 2022-05-23 | |
| PCT/US2023/023285 WO2023230098A1 (en) | 2022-05-23 | 2023-05-23 | Gene therapy compositions and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL317018A true IL317018A (en) | 2025-01-01 |
Family
ID=86896027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL317018A IL317018A (en) | 2022-05-23 | 2023-05-23 | Gene therapy compositions and methods of use thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20260191989A1 (en) |
| EP (1) | EP4529472A1 (en) |
| JP (1) | JP2025517947A (en) |
| KR (1) | KR20250017232A (en) |
| CN (1) | CN119630433A (en) |
| AU (1) | AU2023275457A1 (en) |
| CA (1) | CA3256767A1 (en) |
| CO (1) | CO2024017533A2 (en) |
| IL (1) | IL317018A (en) |
| MX (1) | MX2024014450A (en) |
| WO (1) | WO2023230098A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202323528A (en) * | 2021-10-18 | 2023-06-16 | 美商邏輯生物療法公司 | Gene therapy for the treatment of wilson's disease |
| WO2025229995A1 (en) * | 2024-04-30 | 2025-11-06 | 学校法人自治医科大学 | Vector for nucleic acid introduction, nucleic acid introduction method, polynucleotide, and vector |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2279254B1 (en) | 2008-04-15 | 2017-07-05 | Protiva Biotherapeutics Inc. | Novel lipid formulations for nucleic acid delivery |
| CA3044884A1 (en) | 2009-12-07 | 2011-06-16 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
| BR112014024131A2 (en) | 2012-03-29 | 2017-07-25 | Shire Human Genetic Therapies | ionizable cationic lipids |
| DK2839013T3 (en) | 2012-04-18 | 2020-09-14 | Univ Leland Stanford Junior | NON-DISRUPTIVE-GEN-TARGETING |
| US20150366997A1 (en) | 2012-12-07 | 2015-12-24 | Shire Human Genetics Therapies, Inc. | COMPOSITIONS AND METHODS FOR mRNA DELIVERY |
| TR201909034T4 (en) | 2013-10-25 | 2019-07-22 | Bayer Pharma AG | A new stable formulation. |
| US10612041B2 (en) | 2014-03-21 | 2020-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Genome editing without nucleases |
| WO2015184256A2 (en) | 2014-05-30 | 2015-12-03 | Shire Human Genetic Therapies, Inc. | Biodegradable lipids for delivery of nucleic acids |
| EP3538067A1 (en) | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| MX2020002348A (en) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Methods of making lipid nanoparticles. |
| WO2019089828A1 (en) | 2017-10-31 | 2019-05-09 | Acuitas Therapeutics, Inc. | Lamellar lipid nanoparticles |
| WO2020032986A1 (en) | 2018-08-10 | 2020-02-13 | Logicbio Therapeutics, Inc. | Non-disruptive gene therapy for the treatment of mma |
| KR20220021906A (en) | 2019-04-15 | 2022-02-22 | 로직바이오 테라퓨틱스, 인크. | gene therapy monitoring |
| WO2020219941A1 (en) | 2019-04-26 | 2020-10-29 | Genevant Sciences Gmbh | Lipid nanoparticles |
| US20220275403A1 (en) * | 2019-08-19 | 2022-09-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods And Compositions For Enhancing AAV-Mediated Homologous Recombination Using Ribonucleotide Reductase Inhibitors |
| AU2020385378A1 (en) | 2019-11-22 | 2022-04-07 | Generation Bio Co. | Ionizable lipids and nanoparticle compositions thereof |
| EP4065709A4 (en) * | 2019-11-25 | 2023-11-29 | Baylor College of Medicine | Selective expansion of gene-targeted cells |
-
2023
- 2023-05-23 WO PCT/US2023/023285 patent/WO2023230098A1/en not_active Ceased
- 2023-05-23 AU AU2023275457A patent/AU2023275457A1/en active Pending
- 2023-05-23 CN CN202380049453.0A patent/CN119630433A/en active Pending
- 2023-05-23 EP EP23732753.1A patent/EP4529472A1/en active Pending
- 2023-05-23 KR KR1020247042340A patent/KR20250017232A/en active Pending
- 2023-05-23 IL IL317018A patent/IL317018A/en unknown
- 2023-05-23 CA CA3256767A patent/CA3256767A1/en active Pending
- 2023-05-23 US US18/868,278 patent/US20260191989A1/en active Pending
- 2023-05-23 JP JP2024568986A patent/JP2025517947A/en active Pending
-
2024
- 2024-11-22 MX MX2024014450A patent/MX2024014450A/en unknown
- 2024-12-20 CO CONC2024/0017533A patent/CO2024017533A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN119630433A (en) | 2025-03-14 |
| KR20250017232A (en) | 2025-02-04 |
| AU2023275457A1 (en) | 2024-11-28 |
| JP2025517947A (en) | 2025-06-12 |
| EP4529472A1 (en) | 2025-04-02 |
| US20260191989A1 (en) | 2026-07-09 |
| WO2023230098A9 (en) | 2024-12-12 |
| WO2023230098A1 (en) | 2023-11-30 |
| MX2024014450A (en) | 2025-03-07 |
| CA3256767A1 (en) | 2023-11-30 |
| CO2024017533A2 (en) | 2025-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL299167A (en) | Compositions and methods for treatment of gene therapy patients | |
| GB2605538B (en) | Compositions and methods for delivery of RNA | |
| EP4090752A4 (en) | Plakophillin-2 gene therapy methods and compositions | |
| IL315862A (en) | Angiotensinogen-modulating compositions and methods of use thereof | |
| IL318328A (en) | Compositions including multi-agonist peptides and methods of manufacture and use | |
| IL315305A (en) | Improved igg-degrading enzymes and methods of use thereof | |
| IL316049A (en) | Pharmaceutical compositions of mosunetuzumab and methods of use | |
| IL304123A (en) | Compositions and methods for delivery of rna | |
| GB2622995B (en) | CAS13-based compositions and methods of use thereof | |
| EP4110369A4 (en) | Methods of treatment and related compositions | |
| IL316170A (en) | Pharmaceutical compositions of therapeutic proteins and methods of use | |
| IL327476A (en) | Modified oligonucleotides and methods of use thereof | |
| MX2024014450A (en) | Gene therapy compositions and methods of use thereof | |
| IL318277A (en) | Encrypted rna and methods of its use | |
| IL316562A (en) | High dose endoxifen formulations and methods of use | |
| IL325628A (en) | Coagulation factor xi-modulating compositions and methods of use thereof | |
| IL314226A (en) | Designed cytokine compositions and methods of use | |
| EP4326291A4 (en) | Methods and compositions for genetic modification and therapeutic use of immune cells | |
| SMT202500442T1 (en) | Olanzapine compositions and methods of use | |
| IL311518A (en) | Prekallikrein-modulating compositions and methods of use thereof | |
| GB202319290D0 (en) | Compositions and methods of gene expression | |
| GB202319294D0 (en) | Compositions and methods of gene expression | |
| HK40103646A (en) | Compositions for and methods of improving gene therapy | |
| IL325884A (en) | Compositions comprising GAL475 and methods of using them | |
| IL326294A (en) | Epilepsy compositions and methods of use |